Deals Shaping The Medical Industry, February 2014
Executive Summary
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced December 2013 through January 2014.
You may also be interested in...
Japan Passes New Economic Security Bill – What's The Pharma Impact?
Japan has passed a new law which will require the providers of certain products to cooperate in securing supplies to the country. For the pharma industry, there are a couple of signs which specific drugs will be within the scope of the legislation and how this will impact the sector.
Hengrui’s PD-1 Camrelizumab Moves Step Closer To US Filing
Positive outcomes from a multiregional Phase III trial provide Jiangsu Hengrui Medicine with a milestone in the Chinese firm's quest for globalization, as it looks to succeed where others have had recent setbacks.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Pfizer to boost migraine presence via M&A; Roche’s immunotherapy ambitions take a hit; Biogen’s CEO search gets more complicated; Stoffels lays out new strategy for Galapagos; and mixed results for Japanese majors.